《去势抵抗性前列腺癌诊断和治疗中国专家共识（2019年版）》
Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update).
作者信息
Zhu Yao, Ye Dingwei
机构信息
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Department of Oncology, Shanghai Medical School, Fudan University, Shanghai, People's Republic of China.
出版信息
Cancer Manag Res. 2020 Mar 23;12:2127-2140. doi: 10.2147/CMAR.S236879. eCollection 2020.
Abstract
Currently, the basic treatment of advanced prostate cancer is still endocrine therapy, but almost all patients eventually progress to castration-resistant prostate cancer (CRPC). In 2016, the Chinese Expert Consensus on the Diagnosis and Treatment of CRPC which aimed to help Chinese clinicians formulate treatment plans for CRPC was published. In this 2019 update, the 2016 version was updated with the aim of providing a more appropriate reference for clinical practice, standardizing CRPC patient management, and facilitating decision-making. The consensus is evidence-based and reviews the optimal therapeutic recommendations for CRPC management in China by taking into consideration the clinical characteristics of Chinese patients; drug availability, efficacy and safety; and recent advancements and developments in the international medical arena.
摘要
目前，晚期前列腺癌的基本治疗方法仍是内分泌治疗，但几乎所有患者最终都会进展为去势抵抗性前列腺癌（CRPC）。2016年，旨在帮助中国临床医生制定CRPC治疗方案的《中国CRPC诊断与治疗专家共识》发布。在本次2019年更新中，对2016年版本进行了更新，目的是为临床实践提供更合适的参考，规范CRPC患者管理，并促进决策制定。该共识基于循证医学，通过考虑中国患者的临床特征、药物可及性、疗效和安全性以及国际医学领域的最新进展，对中国CRPC管理的最佳治疗建议进行了综述。
相似文献
1
Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update).《去势抵抗性前列腺癌诊断和治疗中国专家共识（2019年版）》
Cancer Manag Res. 2020 Mar 23;12:2127-2140. doi: 10.2147/CMAR.S236879. eCollection 2020.
2
Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.代表西班牙放射肿瘤学会泌尿肿瘤工作组（URONCOR）的去势抵抗性前列腺癌管理共识。
Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.
3
Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.巴西关于非转移性去势抵抗性前列腺癌诊断和治疗的共识：根据患者合并症，重点关注患者、选择、治疗效果、副作用和医生的看法。
Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. doi: 10.1590/S1677-5538.IBJU.2020.0249.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases.日本前列腺癌骨转移管理专家小组会议
Oncol Ther. 2018 Dec;6(2):157-171. doi: 10.1007/s40487-018-0088-0. Epub 2018 Dec 11.
6
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.了解前列腺癌患者如何看待转移性去势抵抗性前列腺癌的当前治疗选择。
Urol Oncol. 2018 May;36(5):240.e13-240.e20. doi: 10.1016/j.urolonc.2018.01.011. Epub 2018 Feb 15.
7
"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".《非转移性去势抵抗性前列腺癌：巴西专家小组的诊断和治疗建议》
Clin Genitourin Cancer. 2023 Apr;21(2):e58-e69. doi: 10.1016/j.clgc.2022.09.005. Epub 2022 Sep 10.
8
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分：复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
9
[Consensus on castration-resistant prostate cancer management in Spain.].[西班牙去势抵抗性前列腺癌管理共识。]
Arch Esp Urol. 2017 Nov;70(9):777-791.
10
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.化疗初治去势抵抗性前列腺癌的二线激素治疗：美国临床肿瘤学会临时临床意见。
J Clin Oncol. 2017 Jun 10;35(17):1952-1964. doi: 10.1200/JCO.2017.72.8030. Epub 2017 Apr 25.
引用本文的文献
1
Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer Systematic Review.评估肿瘤突变负荷作为个性化癌症免疫治疗的关键生物标志物：一项泛癌系统评价
Cancers (Basel). 2025 Feb 1;17(3):480. doi: 10.3390/cancers17030480.
2
Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.177Lu-PSMA放射性配体疗法中基线碱性磷酸酶对转移性去势抵抗性前列腺癌的预后价值：一项系统评价和荟萃分析
PLoS One. 2024 Dec 12;19(12):e0307826. doi: 10.1371/journal.pone.0307826. eCollection 2024.
3
OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy.OCT4阳性循环肿瘤细胞可能预示着接受阿比特龙加泼尼松治疗的转移性去势抵抗性前列腺癌患者预后不良。
Oncol Lett. 2023 Sep 4;26(4):452. doi: 10.3892/ol.2023.14039. eCollection 2023 Oct.
4
Gender bias in shared decision-making among cancer care guidelines: A systematic review.癌症护理指南中共享决策制定的性别偏见：系统评价。
Health Expect. 2023 Jun;26(3):1019-1038. doi: 10.1111/hex.13753. Epub 2023 Apr 5.
5
The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.前列腺腺癌血管生成的新型转录组学特征可预测临床结局、肿瘤微环境和治疗反应。
Mol Med. 2022 Jul 14;28(1):78. doi: 10.1186/s10020-022-00504-6.
6
Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.前列腺癌临床指南中关于减肥和健康生活方式的建议：系统评价。
Int J Environ Res Public Health. 2022 Jan 27;19(3):1452. doi: 10.3390/ijerph19031452.
7
Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus.印度晚期前列腺癌管理中全身治疗的排序：基于德尔菲法的共识
Oncol Ther. 2022 Jun;10(1):143-165. doi: 10.1007/s40487-021-00181-1. Epub 2022 Jan 13.
8
Drug Repurposing of Pantoprazole and Vitamin C Targeting Tumor Microenvironment Conditions Improves Anticancer Effect in Metastatic Castration-Resistant Prostate Cancer.针对肿瘤微环境条件对泮托拉唑和维生素C进行药物重新利用可提高转移性去势抵抗性前列腺癌的抗癌效果。
Front Oncol. 2021 Jul 7;11:660320. doi: 10.3389/fonc.2021.660320. eCollection 2021.
9
Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.全面分析肿瘤突变负担及其在前列腺癌中的临床意义。
BMC Urol. 2021 Feb 25;21(1):29. doi: 10.1186/s12894-021-00795-7.
10
Reliability and validity test of VES-13 and analysis of influencing factors for the vulnerable condition of patients with advanced castration-resistant prostate cancer.VES-13的可靠性和有效性测试以及晚期去势抵抗性前列腺癌患者脆弱状况的影响因素分析
Pak J Med Sci. 2021 Jan-Feb;37(1):137-141. doi: 10.12669/pjms.37.1.3095.
本文引用的文献
1
Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.中国前列腺癌患者种系 DNA 修复基因突变全景。
Eur Urol. 2019 Sep;76(3):280-283. doi: 10.1016/j.eururo.2019.06.004. Epub 2019 Jun 24.
2
Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.代表西班牙放射肿瘤学会泌尿肿瘤工作组（URONCOR）的去势抵抗性前列腺癌管理共识。
Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.治疗后出现的小细胞神经内分泌前列腺癌的临床和基因组特征：一项多机构前瞻性研究。
J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.
5
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
6
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.IMAAGEN 研究：醋酸阿比特龙和泼尼松对非转移性去势抵抗性前列腺癌患者前列腺特异性抗原和影像学疾病进展的影响。
J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.
7
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.阿帕鲁胺治疗与前列腺癌无转移生存。
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
8
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.恩杂鲁胺用于未经化疗的转移性去势抵抗性前列腺癌男性患者：3期PREVAIL研究的扩展分析
Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.
9
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.去势抵抗性前列腺癌的试验设计与目标：前列腺癌临床试验工作组3的更新建议
J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.
10
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.恩杂鲁胺对比比卡鲁胺用于去势抵抗性前列腺癌：STRIVE 试验。
J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.
Zotero 插件